Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045024 | 1.00 | HPGD (0.35) | HPGDEPHX2MEN1KMT2APARP14 | |
| SCHEMBL19859228 | 0.87 | EPHX2 (0.36) | HPGDEPHX2MEN1KMT2APARP14 | |
| SCHEMBL21045043 | 0.87 | EPHX2 (0.36) | HPGDEPHX2MEN1KMT2APARP14 | |
| SCHEMBL21045023 | 0.85 | EPHX2 (0.40) | HPGDEPHX2MEN1KMT2APARP14 | |
| SCHEMBL19859235 | 0.85 | EPHX2 (0.40) | HPGDEPHX2MEN1KMT2APARP14 | |
| SCHEMBL4522936 | 0.84 | HPGD (0.39) | HPGDEPHX2MEN1KMT2AUSP2 | |
| SCHEMBL21777669 | 0.76 | EPHX2 (0.40) | EPHX2USP2SMN1; SMN2EPHX1USP30 | |
| SCHEMBL27100470 | 0.74 | USP2 (0.42) | EPHX2USP2SMN1; SMN2EPHX1USP30 | |
| SCHEMBL4569995 | 0.73 | CTSS (0.51) | MEN1KMT2AUSP30 | |
| SCHEMBL29310737 | 0.73 | GAA (0.43) | HPGDSMN1; SMN2MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-109562152-B | Drug conjugates containing self-stabilizing linkers with improved physiochemical properties | 西雅图基因公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11944689-B2 | Drug conjugates with self-stabilizing linkers having improved physiochemical properties | SEAGEN INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3496747-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190167806-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEATTLE GENETICS, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190167806-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEATTLE GENETICS, INC. (US) | 2019-06-06 | — | — | US | disclosed |
| WO-2018031690-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEATTLE GENETICS, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| WO-2018031690-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEATTLE GENETICS, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167806-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | HPGD 3836/4885EPHX2 972/4885MEN1 397/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | HPGD 3836/4885EPHX2 972/4885MEN1 397/4885 |
| US-11944689-B2 | Drug conjugates with self-stabilizing linkers having improved physiochemical properties | CD44, CD47, UACA | HPGD 3836/4885EPHX2 972/4885MEN1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.